MX392496B - Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica. - Google Patents
Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica.Info
- Publication number
- MX392496B MX392496B MX2017012694A MX2017012694A MX392496B MX 392496 B MX392496 B MX 392496B MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 392496 B MX392496 B MX 392496B
- Authority
- MX
- Mexico
- Prior art keywords
- glucagon receptor
- fatty liver
- obesity
- alcoholic
- treatment
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 229940122904 Glucagon receptor antagonist Drugs 0.000 title 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142257P | 2015-04-02 | 2015-04-02 | |
| PCT/US2016/025336 WO2016161154A1 (en) | 2015-04-02 | 2016-03-31 | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012694A MX2017012694A (es) | 2018-03-07 |
| MX392496B true MX392496B (es) | 2025-03-24 |
Family
ID=57006366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012694A MX392496B (es) | 2015-04-02 | 2016-03-31 | Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10752693B2 (enExample) |
| EP (1) | EP3277830A4 (enExample) |
| JP (1) | JP6861641B2 (enExample) |
| KR (1) | KR20170138456A (enExample) |
| CN (1) | CN107614695B (enExample) |
| AU (1) | AU2016242935B2 (enExample) |
| CA (1) | CA2980765A1 (enExample) |
| MX (1) | MX392496B (enExample) |
| WO (1) | WO2016161154A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565559A4 (en) * | 2017-01-09 | 2020-07-08 | Temple University - Of The Commonwealth System of Higher Education | PHARMACEUTICAL METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
| SG11201906682YA (en) | 2017-01-27 | 2019-08-27 | Ngm Biopharmaceuticals Inc | Glucagon receptor binding proteins and methods of use thereof |
| KR102686854B1 (ko) * | 2017-08-09 | 2024-07-18 | 사노피 | 지방간 질환 및 지방간염의 치료에서의 glp-1/글루카곤 수용체 작용제 |
| JP2021514662A (ja) * | 2018-03-08 | 2021-06-17 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｔｉｐ−１抗体及びその使用 |
| CN110357959B (zh) * | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
| CN111068042B (zh) * | 2018-10-18 | 2023-10-13 | 中山大学 | 一种多肽化合物在制备治疗非酒精性肝病、特发性肺间质纤维化和动脉硬化药物中的应用 |
| WO2020097054A1 (en) * | 2018-11-06 | 2020-05-14 | Georgetown University | Treating non-alcoholic steatohepatitis with cck inhibitors |
| CN115947849A (zh) | 2018-12-21 | 2023-04-11 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
| WO2025178928A1 (en) * | 2024-02-23 | 2025-08-28 | Remd Biotherapeutics, Inc. | Combination therapy for the treatment of obesity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| US8501686B2 (en) | 2008-06-05 | 2013-08-06 | University Of Michigan | Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects |
| PA8830501A1 (es) * | 2008-06-17 | 2010-07-27 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| CN108410868A (zh) * | 2011-09-20 | 2018-08-17 | Ionis制药公司 | Gcgr表达的反义调节 |
| WO2014181229A2 (en) * | 2013-05-07 | 2014-11-13 | Rinat Neuroscience Corp. | Anti-glucagon receptor antibodies and methods of use thereof |
| US10626179B2 (en) * | 2014-06-08 | 2020-04-21 | Remd Biotherapeutics, Inc. | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
-
2016
- 2016-03-31 CA CA2980765A patent/CA2980765A1/en active Pending
- 2016-03-31 MX MX2017012694A patent/MX392496B/es unknown
- 2016-03-31 EP EP16774227.9A patent/EP3277830A4/en not_active Ceased
- 2016-03-31 JP JP2017550154A patent/JP6861641B2/ja active Active
- 2016-03-31 WO PCT/US2016/025336 patent/WO2016161154A1/en not_active Ceased
- 2016-03-31 CN CN201680030380.0A patent/CN107614695B/zh active Active
- 2016-03-31 AU AU2016242935A patent/AU2016242935B2/en not_active Ceased
- 2016-03-31 KR KR1020177031693A patent/KR20170138456A/ko not_active Ceased
- 2016-03-31 US US15/563,162 patent/US10752693B2/en active Active
-
2020
- 2020-07-14 US US16/928,441 patent/US20200339697A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107614695A (zh) | 2018-01-19 |
| JP6861641B2 (ja) | 2021-04-21 |
| WO2016161154A1 (en) | 2016-10-06 |
| AU2016242935B2 (en) | 2020-10-01 |
| US20180079820A1 (en) | 2018-03-22 |
| US10752693B2 (en) | 2020-08-25 |
| EP3277830A1 (en) | 2018-02-07 |
| US20200339697A1 (en) | 2020-10-29 |
| AU2016242935A1 (en) | 2017-11-09 |
| EP3277830A4 (en) | 2018-11-21 |
| CN107614695B (zh) | 2022-01-25 |
| JP2018512417A (ja) | 2018-05-17 |
| KR20170138456A (ko) | 2017-12-15 |
| CA2980765A1 (en) | 2016-10-06 |
| MX2017012694A (es) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX392496B (es) | Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica. | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| MX2024013960A (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PH12017502359B1 (en) | Glucagon and glp-1 co-agonist compounds | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| PH12016502345A1 (en) | Anti-gitr antibodies and methods of use thereof | |
| MY189692A (en) | Anti-ox40 antibodies and methods of use thereof | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| MX2015016978A (es) | Proteinas de union a antigeno neutralizantes de citomegalovirus. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MX388503B (es) | Uso de anticuerpos antagonistas del receptor de glucagon en el tratamiento de diabétes tipo 1. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| MX2018007925A (es) | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. | |
| MX2018011025A (es) | Metodos para tratar o prevenir la enfermedad del injerto contra huésped. | |
| MA40536A (fr) | Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations | |
| MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
| NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
| MX2017001983A (es) | Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos. | |
| WO2014144616A3 (en) | Anti-alpha v beta 5 antibodies and uses thereof |